Author : Denish Prajapati 1
Date of Publication :1st October 2022
Abstract: The climbing plant Luffa echinata ROXB. (Curcurbitaceae) has been used traditionally to treat a number of diseases. Luffa echinata ROXB. Fruit has been shown in scientific studies to have antioxidant, antidepressant, anxiolytic, antiepileptic, hepatoprotective, anti-cancer, and asthmatic properties. However, there has been little research of asthmatic activity. Using AutoDock 4.2, we investigated the Luffa echinata ROXB. as a anti-asthmatic effect in this study. IL-13 is a powerful stimulator of all interleukins implicated in the inflammatory process connected to asthma. Due to this, phytosterols and its analogue were docked with IL-13 (PDB: 3L5X), and their binding complementarities were assessed in this study. It was found that phytosterols are well accommodated in IL-13's active site. Although the study's limited patient population, asthma can raise the incidence of COVID-19 hospitalisation in people 18 to 49 years old. Therefore, future research is necessary to investigate the ability of Luffa echinata ROXB. against COVID-19.
Reference :
-
- Frieri M. “Asthma concepts in the new millennium: update in asthma pathophysiology”, In Allergy and asthma proceeding: OceanSide; 2005. pp. 83- 88.
- Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. “Safety of inhaled corticosteroids” Proceedings of the American ThoracicSociety.2004;1(3): 1715
- Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, Peters- Golden M, Martinez FJ, “Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients”, American Journal of Respiratory and Critical Care Medicine. 2005; 172(3):379-83.
- Mukherjee PK, “Quality control of herbal drugs: an approach or evaluation of botanicals”, New Delhi: Business Horizons Publication. 2002.
- Harsh mohan; Text book of pathology; jaypee brothers medical publishers New Delhi; 2005.pp 491 – 492. Kaufman G. Asthma: pathophysiology, diagnosis and management. Nurs Stand. 2011;26(5):48. doi:10.7748/ns.26.5.48.s55.
- Pedersen SE, Hurd SS, Lemanske RF Jr, et al. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol. 2011;46(1):1–17. doi:10.1002/ppul.21321.
- Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J. 2007;24(12):823–830. doi:10.1136/emj.2007.052050.
- Adams BK, Cydulka RK. Asthma evaluation and management. Emerg Med Clin N Am. 2003;21(2):315–330. doi:10.1016/S0733-8627(03)00015-4.
- Barnes PJ. Drugs for asthma. Br J Pharmacol. 2006;147(S1):S297–S303. doi:10.1038/sj.bjp.0706437. [11] DiMartino SJ. Idiopathic inflammatory myopathy: treatment options. Curr Rheumatol Rep. 2008;10(4):321. doi:10.1007/s11926-008-0051-4.
- Amaral-Machado L, Oliveira WN, Moreira-Oliveira SS, et al. Use of natural products in asthma treatment. Evid. Based Complementary Altern. Med. 2020;2020:1–35. doi:10.1155/2020/1021258.
- Patel Ramesh, Jawaid Talha, Gautam Piyush and Dwivedi, “Herbal remedies for Gestroprotective Action: A Review.” Int. J. of Phaytopharm. 2012, 2, 30-38.
- Kumar RK, Herbert C, Foster P. The “Classical” ovalbumin challenge model of asthma in mice. Curr. Drug Targets. 2008;9(6):485–494. doi:10.2174/138945008784533561.
- Khodoun MV, Orekhova T, Potter C, et al. Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med. 2004;200(7):857–870. doi:10.1084/jem.20040598.
- Liu L, Rich BE, Inobe J-I, et al. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol. 1998;10(8):1017–1026. doi:10.1093/ intimm/10.8.1017.
- [17] Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21 (1):425–456. doi:10.1146/annurev.immunol.21.120601.141142.
- Elias JA, Lee CG, Zheng T, et al. Interleukin-13 and leukotrienes: an intersection of pathogenetic schema. Am J Respir Cell Mol Biol. 2003;28(4):401–404. doi:10.1165/rcmb.F264.
- Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202(1):175–190. doi:10.1111/j.0105-2896.2004.00215.x.
- Giri s, Lokesh CR, Sahu S, Gupta N, “Luffa echinata: Healer plant or potential killer”, asian journal of postgraduate medicine, volume 60, issue (1),jan and march-2014,72-74.
- Deepak Kailasiya, S.K..Jain,Shashi Alok, “Phytochemical screening on the aerial part of the luffa echinata Lin.”, International Jounal of pharmaceutical sciences and research, 2011, vol 2(9), 2446-2450.
- Indian Medicinal Plants Vol. : 3, Kirtikar K. R. & Basu B. D., Dehradun, India : International Book Distributor 2005, Page No. : 1125-1126.